- Organizations: AbbVie
Pipeline
FDA accepts Aldeyra's reproxalap DED NDA resubmission
With a new PDUFA data set for April 2024, the company also announced expansions to its option agreement with AbbVie.
Business
AbbVie and Ripple Therapeutics to develop glaucoma intracameral implant
Collaboration features Ripple’s RTC-620, a sustained-release drug implant with repeat dosing for lowering IOP in OAG and OHT patients.
Business
AbbVie names longtime executive as new CEO
Effective July 1, current president and chief operating officer (COO) Robert A. Michael will take the helm.
Pipeline
Aldeyra and AbbVie agree to exclusive licensing option for reproxalap
Agreement follows FDA concerns regarding the DED investigational compound’s clinical data.
Research
How effective is twice-daily pilocarpine HCl 1.25% for presbyopia?
Research provides efficacy and safety details for Vuity’s dosing regimen.
Products
FDA approves Allergan’s twice-daily dosing drops for presbyopia
Drop builds on previous once-daily Vuity drops for adults; extended duration lasts up to 9 hours.
Research